Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
68.58
Nov 20 • 3:21 PM ET Dollar change+0.86 Percentage change(1.27%)
Nov 19, 12:40 PMTD Cowen named Royalty Pharma its top pharma pick for 2027 and raised its price target to $80.
Index
RUI
Market Cap
39.34B
Enterprise Value
50.34B
Income
671.25M
Sales
2.62B
Book/sh
15.34
Cash/sh
0.95
Employees
100
IPO
Jun 16, 2020
P/E
44.62
Forward P/E
11.70
PEG
1.12
P/S
15.03
P/B
4.47
P/C
72.20
P/FCF
13.14
EV/EBITDA
29.27
EV/Sales
19.24
Quick Ratio
1.29
Current Ratio
1.29
Debt/Eq
1.26
LT Debt/Eq
1.11
Option/Short
Yes / Yes
EPS (ttm)
1.54
EPS next Y
5.86
EPS next Q
1.57
EPS this Y
11.70%
EPS next Y
8.65%
EPS next 5Y
10.49%
EPS past 3/5Y
163.11% -7.26%
Sales past 3/5Y
2.06% 2.30%
EPS Y/Y TTM
-12.26%
Sales Y/Y TTM
11.34%
EPS Q/Q
-51.34%
Sales Q/Q
13.26%
Insider Own
6.32%
Insider Trans
-2.63%
Inst Own
88.57%
Inst Trans
3.22%
ROA
3.46%
ROE
10.13%
ROIC
4.65%
Gross Margin
99.81%
Oper. Margin
65.53%
Profit Margin
25.65%
SMA20
1.45%
SMA50
10.07%
SMA200
24.10%
Trades
Shs Outstand
445.82M
Shs Float
417.14M
52W High
70.37 -2.54%
52W Low
37.31 83.81%
Volatility
1.99% 2.29%
ATR (14)
1.49
RSI (14)
63.81
Beta
0.35
Rel Volume
0.69
Avg Volume
3.19M
Volume
1,992,981
Perf Week
-1.05%
Perf Month
7.58%
Perf Quarter
11.82%
Perf Half Y
25.83%
Perf YTD
77.48%
Perf Year
78.64%
Perf 3Y
154.66%
Perf 5Y
65.01%
Perf 10Y
-
Prev Close
67.72
Price
68.58
Change %
1.27%
Consensus
Buy
Avg. Price Target
$76.43
Implied Upside
+11.4%
Analysts10incl. previous ratings
Rating Distribution9 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jan 30, 2026Upgrade
UBS logoUUBS
Neutral → Buy$49-28.6%
Sep 30, 2025Initiated
GS logoGGoldman
Buy$42-38.8%
May 16, 2025Initiated
MS logoMMorgan Stanley
Overweight$51-25.6%
Jun 03, 2024Downgrade
UBS logoUUBS
Buy → Neutral$28-59.2%
Jun 14, 2022Resumed
UBS logoUUBS
Buy$47-31.5%
May 13, 2022Initiated
BNS logoBScotiabank
Sector Outperform$53-22.7%
Apr 27, 2022Initiated
GS logoGGoldman
Buy$56-18.3%
Apr 14, 2022Upgrade
JPM logoJJP Morgan
Neutral → Overweight$50-27.1%
Apr 06, 2022Resumed
MS logoMMorgan Stanley
Overweight$48-30.0%
Oct 29, 2021Upgrade
C logoCCitigroup
Neutral → Buy$50-27.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hite ChristopherEVP & Chairman, PartneringNov 17 '26Sale68.15100,0006,814,710177,523Nov 18 04:15 PM
Coyne Terrance P.EVP & CFONov 16 '26Sale68.87232,53616,014,3030Nov 18 04:14 PM
Coyne Terrance P.EVP & CFONov 17 '26Sale68.3024,5861,679,3390Nov 18 04:14 PM
Urist MarshallEVP, Research & InvestmentsNov 16 '26Sale69.5025,0001,737,490125,000Nov 18 04:13 PM
SCH Investment Partners LLCOfficerNov 17 '26Proposed Sale67.84150,00010,176,000Nov 17 04:35 PM
Terrance CoyneOfficerNov 16 '26Proposed Sale68.53257,12217,619,285Nov 16 07:32 PM
Sandy Lamm LLCOfficerNov 16 '26Proposed Sale68.53150,00010,278,750Nov 16 04:55 PM
Urist MarshallEVP, Research & InvestmentsOct 05 '26Sale57.104,126235,5950Oct 05 05:12 PM
Urist MarshallOfficerOct 05 '26Proposed Sale57.104,126235,595Oct 05 04:02 PM
Urist MarshallEVP, Research & InvestmentsSep 28 '26Sale57.884,126238,8134,126Sep 30 04:32 PM
Urist MarshallOfficerSep 28 '26Proposed Sale57.884,126238,813Sep 28 04:09 PM
Hite ChristopherEVP & Chairman, PartneringSep 22 '26Sale58.53100,0005,853,095270,401Sep 24 04:10 PM
SCH Investment Partners LLCOfficerSep 22 '26Proposed Sale58.47100,0005,846,972Sep 22 04:50 PM
Hite ChristopherEVP & Chairman, PartneringAug 18 '26Sale59.97100,0005,997,250370,401Aug 19 04:20 PM
SCH Investment Partners LLCOfficerAug 18 '26Proposed Sale60.12100,0006,012,000Aug 18 04:45 PM
Coyne Terrance P.EVP & CFOAug 13 '26Sale58.6811,002645,5510Aug 17 05:01 PM
Terrance CoyneOfficerAug 13 '26Proposed Sale58.5611,002644,277Aug 13 04:43 PM
Errol B. De SouzaFormer AffiliateAug 12 '26Proposed Sale57.79206,35211,925,082Aug 12 06:32 PM
Errol B. De SouzaFormer AffiliateAug 12 '26Proposed Sale57.79125,0007,223,750Aug 12 06:28 PM
Urist MarshallEVP, Research & InvestmentsJul 01 '26Sale55.889,099508,4540Jul 02 04:10 PM
Hite ChristopherEVP & Chairman, PartneringJun 30 '26Sale56.52100,0005,651,813459,399Jul 02 04:08 PM
Hite ChristopherEVP & Chairman, PartneringJun 30 '26Sale56.4630,0001,693,65840,000Jul 02 04:08 PM
Urist MarshallOfficerJul 01 '26Proposed Sale55.889,099508,454Jul 01 04:18 PM
SCH Investment Partners LLCOfficerJun 30 '26Proposed Sale57.09100,0005,709,000Jul 01 08:24 AM
Urist MarshallEVP, Research & InvestmentsJun 24 '26Sale55.189,098502,0679,099Jun 25 05:13 PM
Hite ChristopherEVP & Chairman, PartneringJun 23 '26Sale54.40150,0008,159,277559,399Jun 25 05:11 PM
Urist MarshallOfficerJun 24 '26Proposed Sale55.189,098502,067Jun 24 04:14 PM
Christopher HiteOfficerJun 23 '26Proposed Sale55.3530,0001,660,500Jun 23 04:48 PM
SCH Investment Partners LLCOfficerJun 23 '26Proposed Sale54.45150,0008,166,766Jun 23 04:46 PM
Coyne Terrance P.EVP & CFOMay 26 '26Sale53.9864,3993,476,1160May 28 04:48 PM
Terrance CoyneOfficerMay 26 '26Proposed Sale53.8664,3993,468,530May 26 05:49 PM
Urist MarshallEVP, Research & InvestmentsMay 20 '26Sale52.7513,684721,83818,197May 21 09:20 PM
Urist MarshallOfficerMay 20 '26Proposed Sale52.7513,684721,837May 20 04:23 PM
Urist MarshallEVP, Research & InvestmentsMay 14 '26Sale53.0613,684726,13731,881May 15 04:38 PM
Norden GregoryDirectorMay 14 '26Sale53.003,045161,385191,803May 15 04:37 PM
Norden GregoryOfficerMay 14 '26Proposed Sale53.003,045161,385May 14 05:28 PM
Urist MarshallOfficerMay 14 '26Proposed Sale53.0613,684726,138May 14 05:22 PM
Coyne Terrance P.EVP & CFOApr 28 '26Sale49.7834,7911,731,8400Apr 30 05:54 PM
Terrance CoyneOfficerApr 28 '26Proposed Sale49.5434,7911,723,546Apr 28 05:00 PM
Coyne Terrance P.EVP & CFOApr 01 '26Sale48.3334,7911,681,51232,916Apr 02 05:58 PM
Terrance CoyneOfficerApr 01 '26Proposed Sale48.4934,7911,687,016Apr 01 04:55 PM
Coyne Terrance P.EVP & CFOMar 23 '26Sale45.5334,7911,583,98943,886Mar 25 05:05 PM
Terrance CoyneOfficerMar 23 '26Proposed Sale45.6134,7911,586,818Mar 23 04:43 PM
George LloydOfficerMar 19 '26Proposed Sale45.5336,5181,662,665Mar 19 05:12 PM
George LloydOfficerMar 18 '26Proposed Sale45.79100,4624,600,155Mar 18 06:02 PM
Coyne Terrance P.EVP & CFOMar 02 '26Sale46.7834,7911,627,53445,761Mar 04 05:11 PM
George LloydOfficerMar 04 '26Proposed Sale47.43136,9806,496,961Mar 04 04:52 PM
Terrance CoyneOfficerMar 02 '26Proposed Sale47.4734,7911,651,529Mar 02 05:26 PM
Coyne Terrance P.EVP & CFOFeb 23 '26Sale45.3234,7911,576,60647,636Feb 25 04:08 PM
Terrance CoyneOfficerFeb 23 '26Proposed Sale45.4734,7911,581,947Feb 23 05:06 PM
Coyne Terrance P.EVP & CFOFeb 03 '26Sale42.84114,9544,924,99723,972Feb 04 05:07 PM
Coyne Terrance P.EVP & CFOFeb 02 '26Sale42.08108,4244,562,90530,167Feb 04 05:07 PM
Coyne Terrance P.EVP & CFOFeb 04 '26Sale43.2920,163872,91322,885Feb 04 05:07 PM
Terrance CoyneOfficerFeb 03 '26Proposed Sale42.97135,1175,805,977Feb 03 05:31 PM
Terrance CoyneOfficerFeb 02 '26Proposed Sale42.36108,4244,592,841Feb 02 05:28 PM
Urist MarshallEVP, Research & InvestmentsJan 30 '26Sale41.0920,000821,8100Feb 02 04:59 PM
Urist MarshallEVP, Research & InvestmentsJan 23 '26Sale40.2620,000805,11020,000Jan 26 04:10 PM
Coyne Terrance P.EVP & CFOJan 20 '26Sale39.3569,5822,737,94036,010Jan 23 04:48 PM
Urist MarshallEVP, Research & InvestmentsJan 16 '26Sale39.5220,000790,34640,000Jan 20 05:00 PM
Terrance CoyneOfficerJan 20 '26Proposed Sale39.0969,5822,719,960Jan 20 04:55 PM
Urist MarshallEVP, Research & InvestmentsJan 09 '26Sale40.7820,000815,63460,000Jan 13 05:37 PM
George LloydOfficerJan 07 '26Proposed Sale41.39495,86020,523,645Jan 07 05:03 PM
Coyne Terrance P.EVP & CFOJan 02 '26Sale38.4269,5822,673,04139,760Jan 06 04:18 PM
Urist MarshallEVP, Research & InvestmentsJan 02 '26Sale38.4820,000769,65080,000Jan 06 04:17 PM
Terrance CoyneOfficerJan 02 '26Proposed Sale38.8669,5822,703,957Jan 02 06:22 PM
Urist MarshallEVP, Research & InvestmentsDec 26 '25Sale39.3220,000786,380100,000Dec 29 04:58 PM
Urist MarshallEVP, Research & InvestmentsDec 19 '25Sale38.3820,000767,582120,000Dec 22 04:09 PM
Lloyd George W.EVP, Investments & CLODec 17 '25Sale38.5779,3463,060,28030,654Dec 19 05:24 PM
Lloyd George W.EVP, Investments & CLODec 18 '25Sale38.5030,6541,180,0530Dec 19 05:24 PM
Urist MarshallEVP, Research & InvestmentsDec 16 '25Sale38.3220,000766,420140,000Dec 17 05:43 PM
Coyne Terrance P.EVP & CFODec 15 '25Sale38.3669,5822,669,17243,510Dec 17 05:39 PM
Sandy Lamm LLCOfficerDec 16 '25Proposed Sale38.36160,0006,137,600Dec 16 09:41 PM
Terrance CoyneOfficerDec 15 '25Proposed Sale38.5369,5822,680,994Dec 15 06:22 PM
Urist MarshallEVP, Research & InvestmentsDec 05 '25Sale39.1523,334913,591160,000Dec 09 05:00 PM
Urist MarshallEVP, Research & InvestmentsDec 05 '25Sale39.1518,242714,2247,398Dec 09 05:00 PM
Lloyd George W.EVP, Investments & CLODec 03 '25Sale39.77110,0004,375,008110,000Dec 05 05:01 PM
Coyne Terrance P.EVP & CFODec 01 '25Sale39.8769,5822,773,95647,260Dec 03 05:11 PM
Urist MarshallEVP, Research & InvestmentsDec 01 '25Sale39.9323,333931,633183,334Dec 03 05:10 PM
Urist MarshallEVP, Research & InvestmentsDec 01 '25Sale39.9018,242727,85625,640Dec 03 05:10 PM
Terrance CoyneOfficerDec 01 '25Proposed Sale39.9069,5822,776,322Dec 01 05:53 PM
Urist MarshallOfficerDec 01 '25Proposed Sale39.9036,4841,455,712Dec 01 05:10 PM
Sandy Lamm LLCOfficerDec 01 '25Proposed Sale19.9346,667930,232Dec 01 04:48 PM
Coyne Terrance P.EVP & CFONov 24 '25Sale38.5569,5822,682,50551,010Nov 26 05:01 PM
Terrance CoyneOfficerNov 24 '25Proposed Sale39.7569,5822,765,884Nov 24 05:24 PM
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
FounderMr. Pablo Legorreta
Executive VP & CFOMr. Terrance P. Coyne
Chairman of Partnering & InvestmentsMr. Christopher Hite
Ph.D.Dr. Marshall Jonathan Urist M.D.
Executive Vice President of Partnering & InvestmentsMr. Greg Butz